Rapamune, Sirolimus News

To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events.

BACKGROUND: Epstein-Barr virus-associated smooth muscle tumors in adult kidney transplant recipients are rare.

It develops and provides novel solutions for the treatment of complex coronary artery disease.

ISLAMABAD: A new study has demonstrated that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons.

The introduction of the COMBO Stent is in conjunction with the company's receipt of a CE Mark for the product and involves a sales roll-out in The COMBO Dual Therapy Stent is the first stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of OrbusNeich's proven pro-healing technology with an ... (more)

Main Category: Heart Disease Also Included In: Cardiovascular / Cardiology ; Medical Devices / Diagnostics Article Date: 24 May 2013 - 1:00 PDT The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal ... (more)

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today.

Final 6 and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr.

The BIOFLOW-II substudy used intravascular ultrasound and optical coherence tomography to quantitatively assess neointimal hyperplasia and stent apposition at nine months after treating patients with symptomatic coronary artery disease due to de novo stenotic lesions.